Key Drivers
- Margin Strength
- Cash Burn
- Rising Leverage
AIAI Summary
TGTX has shifted from a speculative biotech story to a high-conviction commercial execution play driven by BRIUMVI, but with the stock already rerated, the investment case now hinges on sustained sales growth and eventual free-cash-flow conversion while managing rising leverage, single-product concentration, and a less forgiving valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Cash Burn
- •Rising Leverage
TGTX has strong gross margins and liquidity, but rising leverage, negative cash flow, and uneven earnings quality temper the outlook as valuation becomes richer.
Price Behavior
Key Price Behavior Insights:
- •Breakout momentum
- •Near-term pullback
- •Key support watch
TGTX remains in a constructive uptrend over the last month, but after a sharp breakout to $43.14 it has pulled back to $39.50 and may need to consolidate above $38.31 before another push higher.
Sharp breakout to $43.14 followed by an 8%+ pullback to $39.50
Sentiment & News
Key News Insights:
- •Briumvi Growth
- •Guidance Raise
- •EPS Miss
TG Therapeutics' strong Briumvi sales and raised 2026 guidance offset a Q1 EPS miss, keeping the stock supported despite near-term resistance.
The update is mildly positive for the stock because stronger revenue momentum and higher guidance likely outweigh the earnings shortfall in the near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings